Treatment Experienced Or Naive Hiv 1 Patients Therapeutics
1. Isentress patent expiration
Treatment: Treatment of hiv infection
ISENTRESS's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(3 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(4 years from now) | |
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 years ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(2 years ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 years ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 9 months ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Dosage: TABLET, CHEWABLE; POWDER; TABLET
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
